

Applicant's personal details

Committee: CDNM

Member's name: GEORGE E. GRIFFIN

Principal position(s): Emeritus Professor of Infectious Diseases and Medicine  
St. GEORGE'S UNIVERSITY OF LONDON

Please state the job title and the employer, and if you hold several positions, please state the scope of each position.

Ancillary positions:

Please briefly describe the activities involved in each position, and state whether they are remunerated or not.

PRESIDENT FEDERATION OF EUROPEAN ACADEMIES OF MEDICINE  
CHAIR SAB XELLA PHARMACEUTICALS, Copenhagen

The only remuneration is from SAB XELLA.

GEG

### Personal financial interests

This relates to whether you will derive financial gain from (specific outcomes arising from) the recommendation or the guideline.

Examples:

- Employed by a company that operates in the field to which the recommendation/guideline relates.
- Paid consultancy services in the business sector or for an interest group.
- Direct financial interests in a company (shares or stock options).
- Ownership of a product patent.

PATD CONSULTANCY: SCIENTIFIC ADVISORY BOARD  
XELLIA, Copenhagen (provide scientific advice on  
antimicrobial agents)

### Personal relationships

Are there people close to you who could benefit from specific outcomes arising from the recommendation? Examples are relatives once removed, partners, friends or close colleagues.

NIL

GEG

### Externally funded research

This relates to participation in research funded by semi-government/governmental organisations, funds or industry, where the financier may have an interest in (specific outcomes arising from) the recommendation or guideline.

NIL

### Interests pertaining to intellectual property and reputation

This situation may arise if you stand to benefit from (specific outcomes arising from) the recommendation or the guideline without such benefit being of a financial nature. This includes advantages derived from intellectual property or recognition, for instance.

Examples:

- Increased recognition for intellectual property due to the committee's work.
- Safeguards to your own reputation/position, the position of the employer or other interest organisations, or acquisition of recognition.
- Unique, specialist expertise on the areas and sub-areas covered by the recommendation/guideline, offering the potential for 'commodification'. This may concern a medical product, procedure or intervention, as well as a new theoretical concept or model or a new organisational or logistical approach.
- Figurehead for a patient organisation or professional association.

I am President of European Academies of Medicine  
and as such have wide ranging discussions on  
Medicine. Involved in discussion of 'Shortages of Medicines'

September 2020

OFG

**Other interests**

Do you or those around you have any other interests that could be a source of potential embarrassment to you, your environment or the organisation if made public? NIL

**I, the undersigned**

1. declare that I have read the Code for the prevention of improper influence due to conflicts of interest;
- I. declare that I have listed all relevant relationships and interests in good faith;
- II. declare that I will immediately report any interim changes in the interests reported.

Signature of prospective committee member:

Date: Oct 1 2020

**Decision (to be completed by the requesting organisation)**

Member's name: George E. Griffin

Committee: Development of New Medicins (CDNM)

There are no circumstances precluding participation in the committee.

Participation in the committee is permitted subject to the condition that the expert will not participate in deliberations concerning the examination of and decision-making on:

Participation in the committee is permitted subject to another condition, i.e.:

Although participation in the committee cannot be permitted, the expert may provide the committee with the required expertise by means of a hearing procedure conducted for the purpose of examining and decision-making on the dossier.

Participation in the committee cannot be permitted due to an excessive potential risk of improper influence.

Name: .....

Position: .....

Date: .....

Initials: .....

Explanation (optional):

.....

## TRANSLATION OF CODE TER VOORKOMING VAN ONEIGENLIJKE BEÏNVLOEDING DOOR BELANGENVERSTRENGELING. KNAW, 08-11-2019

**More detailed explanation of relationships and interests (optional):**

## Oordeel (in te vullen door verzoekende organisatie)

---

Naam lid

George E. Griffin

Commissie

Committee Development of New Medicines

- geen belemmeringen voor deelname aan commissie.
- deelname aan commissie onder de volgende voorwaarde: dat betrokkenen zich uit de beraadslaging terugtrekt bij behandeling en besluitvorming van
- deelname aan commissie onder een andere voorwaarde, namelijk
- geen deelname aan commissie mogelijk, maar inbreng van gewenste expertise in commissie mogelijk door middel van hoorprocedure bij de behandeling en besluitvorming van het dossier.
- geen deelname aan commissie mogelijk in verband met inschatting van te hoog risico op oneigenlijke beïnvloeding.

Naam

Mr. Mieke Zaanen

Functie

Algemeen directeur KNAW

Datum

9 oktober 2020

Paraaf

Toelichting (optioneel)

## Nadere toelichting relaties en belangen (optioneel)

---